Payment overview · 2025
General Payments
$831.14
50 reported records · 23 companies
Healthcare provider profile · identity verified
Charles E Hendrix, Jr., M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VINCENNES, IN · NPI 1437101128
Verified facts
What the public records show
CMS Open Payments records show Charles E Hendrix, Jr., M.D. received $831.14 in general payments during 2025 across 50 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 10.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Gemtesa, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Rexulti, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 995 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $83.41 | 10.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.00 | 9.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $79.85 | 9.6% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.81 | 8.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.36 | 7.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.93 | 6.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.86 | 5.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.27 | 5.2% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $40.57 | 4.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.04 | 4.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.99 | 4.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.62 | 3.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.70 | 2.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.49 | 2.3% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $17.85 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.59 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.34 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.01 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.16 | 1.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.51 | 1.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $14.34 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.87 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.57 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $831.14 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $83.41 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $80.90 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.97 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.36 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.79 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $46.89 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.27 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.27 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.99 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $32.59 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.06 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.06 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.62 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 44 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 995 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 131 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 244 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 180 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 28 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 104 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
106 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
179 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
244 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
44 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
104 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
244 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
97 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
180 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
995 | 103 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
131 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1814 | 304 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1611 | 314 |
| Furosemide | Furosemide | 1018 | 199 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1009 | 231 |
| Amlodipine Besylate | Amlodipine Besylate | 1004 | 197 |
| Eliquis | Apixaban | 995 | 103 |
| Lisinopril | Lisinopril | 938 | 212 |
| Potassium Chloride | Potassium Chloride | 900 | 175 |
| Gabapentin | Gabapentin | 834 | 160 |
| Omeprazole | Omeprazole | 833 | 182 |
| Losartan Potassium | Losartan Potassium | 829 | 159 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 714 | 141 |
| Metoprolol Succinate | Metoprolol Succinate | 712 | 159 |
| Alprazolam | Alprazolam | 688 | 148 |
| Carvedilol | Carvedilol | 648 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 574 | 122 |
| Metformin Hcl | Metformin Hcl | 572 | 129 |
| Tramadol Hcl | Tramadol Hcl | 542 | 132 |
| Prednisone | Prednisone | 513 | 195 |
| Escitalopram Oxalate | Escitalopram Oxalate | 486 | 97 |
| Famotidine | Famotidine | 448 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 435 | 109 |
| Montelukast Sodium | Montelukast Sodium | 430 | 99 |
| Lorazepam | Lorazepam | 429 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 428 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 405 | 90 |
| Warfarin Sodium | Warfarin Sodium | 397 | 52 |
| Sertraline Hcl | Sertraline Hcl | 386 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 364 | 81 |
| Simvastatin | Simvastatin | 358 | 72 |
| Meloxicam | Meloxicam | 323 | 80 |
| Tizanidine Hcl | Tizanidine Hcl | 306 | 79 |
| Ropinirole Hcl | Ropinirole Hcl | 293 | 50 |
| Glimepiride | Glimepiride | 292 | 74 |
| Memantine Hcl | Memantine Hcl | 289 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 286 | 54 |
| Mirtazapine | Mirtazapine | 268 | 52 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 266 | 131 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 252 | 40 |
| Jardiance | Empagliflozin | 244 | 37 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 231 | 45 |
| Allopurinol | Allopurinol | 228 | 49 |
| Ondansetron Hcl | Ondansetron Hcl | 225 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 223 | 39 |
| Trazodone Hcl | Trazodone Hcl | 220 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 218 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 216 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 206 | 76 |
| Xarelto | Rivaroxaban | 206 | 20 |
| Ezetimibe | Ezetimibe | 200 | 39 |
| Cefuroxime | Cefuroxime Axetil | 197 | 154 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 193 | 42 |
| Levetiracetam | Levetiracetam | 193 | 26 |
| Donepezil Hcl | Donepezil Hcl | 185 | 42 |
| Spironolactone | Spironolactone | 183 | 34 |
| Clonazepam | Clonazepam | 182 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 182 | 43 |
| Ozempic | Semaglutide | 180 | 27 |
| Farxiga | Dapagliflozin Propanediol | 179 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 162 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 161 | 42 |
| Divalproex Sodium | Divalproex Sodium | 152 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 150 | 39 |
| Myrbetriq | Mirabegron | 148 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 148 | 24 |
| Valsartan | Valsartan | 148 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 147 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 41 |
| Pregabalin | Pregabalin | 140 | 25 |
| Torsemide | Torsemide | 137 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 136 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 133 | 94 |
| Diclofenac Sodium | Diclofenac Sodium | 133 | 34 |
| Gemtesa | Vibegron | 131 | 12 |
| Irbesartan | Irbesartan | 129 | 29 |
| Finasteride | Finasteride | 123 | 20 |
| Enalapril Maleate | Enalapril Maleate | 122 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 122 | 30 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 121 | 23 |
| Topiramate | Topiramate | 120 | 11 |
| Olanzapine | Olanzapine | 118 | 23 |
| Meclizine Hcl | Meclizine Hcl | 117 | 56 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 116 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 116 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 116 | 27 |
| Cefadroxil | Cefadroxil | 115 | 74 |
| Buspirone Hcl | Buspirone Hcl | 113 | 30 |
| Cefdinir | Cefdinir | 111 | 90 |
| Bumetanide | Bumetanide | 108 | 18 |
| Baclofen | Baclofen | 107 | 15 |
| Linzess | Linaclotide | 106 | 17 |
| Cephalexin | Cephalexin | 105 | 50 |
| Temazepam | Temazepam | 105 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 103 | 22 |
| Amoxicillin | Amoxicillin | 101 | 71 |
| Januvia | Sitagliptin Phosphate | 101 | 19 |
| Alendronate Sodium | Alendronate Sodium | 98 | 21 |
| Atenolol | Atenolol | 97 | 24 |
| Entresto | Sacubitril/Valsartan | 97 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 96 | 59 |
| Risperidone | Risperidone | 96 | 21 |
| Azithromycin | Azithromycin | 93 | 62 |
| Clonidine Hcl | Clonidine Hcl | 93 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 93 | 20 |
| Chlorthalidone | Chlorthalidone | 92 | 14 |
| Nyamyc | Nystatin | 91 | 34 |
| Bupropion Xl | Bupropion Hcl | 89 | 18 |
| Nystatin | Nystatin | 89 | 51 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 15 |
| Celecoxib | Celecoxib | 88 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 88 | 15 |
| Aripiprazole | Aripiprazole | 87 | 12 |
| Estradiol | Estradiol | 87 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 87 | 47 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 86 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 19 |
| Synthroid | Levothyroxine Sodium | 82 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 80 | 17 |
| Novolog Flexpen | Insulin Aspart | 80 | 20 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 78 | 37 |
| Latanoprost | Latanoprost | 76 | 15 |
| Nifedipine Er | Nifedipine | 76 | suppressed |
| Ondansetron Odt | Ondansetron | 75 | 35 |
| Oxybutynin Chloride | Oxybutynin Chloride | 75 | 15 |
| Fluconazole | Fluconazole | 74 | 48 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 72 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 49 |
| Lactulose | Lactulose | 71 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 70 | 15 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 70 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 70 | 20 |
| Ibuprofen | Ibuprofen | 68 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 11 |
| Midodrine Hcl | Midodrine Hcl | 66 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 21 |
| Lamotrigine | Lamotrigine | 65 | 11 |
| Tradjenta | Linagliptin | 64 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 63 | 18 |
| Sucralfate | Sucralfate | 61 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 60 | 27 |
| Benazepril Hcl | Benazepril Hcl | 60 | 15 |
| Cilostazol | Cilostazol | 60 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 59 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 57 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 57 | 36 |
| Carbamazepine | Carbamazepine | 56 | suppressed |
| Naproxen | Naproxen | 56 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 56 | suppressed |
| Tresiba | Insulin Degludec | 55 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 55 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 53 | suppressed |
| Fentanyl | Fentanyl | 52 | suppressed |
| Glipizide | Glipizide | 51 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 50 | suppressed |
| Nitroglycerin | Nitroglycerin | 49 | 33 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 48 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Humalog | Insulin Lispro | 47 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 47 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 46 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | suppressed |
| Premarin | Estrogens, Conjugated | 46 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 44 | 43 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | suppressed |
| Glipizide Er | Glipizide | 42 | suppressed |
| Hydrocortisone | Hydrocortisone | 42 | 21 |
| Methocarbamol | Methocarbamol | 42 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 41 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 41 | 32 |
| Fiasp | Insulin Aspart (Niacinamide) | 40 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | suppressed |
| Verapamil Er | Verapamil Hcl | 40 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Loperamide | Loperamide Hcl | 38 | 16 |
| Anastrozole | Anastrozole | 37 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 37 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | 11 |
| Metolazone | Metolazone | 37 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 36 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 35 | suppressed |
| Perphenazine | Perphenazine | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Rexulti | Brexpiprazole | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | 11 |
| Indapamide | Indapamide | 33 | suppressed |
| Scopolamine | Scopolamine | 33 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 32 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 32 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 32 | suppressed |
| Clozapine | Clozapine | 31 | suppressed |
| Olanzapine Odt | Olanzapine | 31 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Cimetidine | Cimetidine | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Dofetilide | Dofetilide | 30 | suppressed |
| Safetyglide Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 30 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 17 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 27 | 22 |
| Roflumilast | Roflumilast | 27 | suppressed |
| Triazolam | Triazolam | 27 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 26 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 22 |
| Letrozole | Letrozole | 26 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Cartia Xt | Diltiazem Hcl | 25 | 12 |
| Mupirocin | Mupirocin | 25 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 24 | suppressed |
| Dexamethasone | Dexamethasone | 24 | 16 |
| Estradiol (Once Weekly) | Estradiol | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Insulin Syringe | Syrge-Ndl,ins 0.3 Ml Half Mark | 24 | suppressed |
| Invokana | Canagliflozin | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 23 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 18 |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Ertapenem | Ertapenem Sodium | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 16 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Droxidopa | Droxidopa | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 17 | suppressed |
| Niacin Er | Niacin | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Tobramycin | Tobramycin | 16 | 15 |
| Xtampza Er | Oxycodone Myristate | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Daptomycin | Daptomycin | 15 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Glucagon Emergency Kit | Glucagon | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,safe,1ml | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $831.14 · 50 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, AREXVY, ARISTADA, AUSTEDO XR, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LEQVIO, LYBALVI, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, SHINGRIX, SX-ONE MICROKNIFE, TRELEGY ELLIPTA, UBRELVY, UZEDY, VOQUEZNA, XIFAXAN, ZEPBOUND | 25 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error